

**FOR APIs/Bulk Drugs/Excipients**

The Chairman  
UCPMP Committee  
IDMA Mumbai

**Sub: Clarification and Undertaking on Marketing Activities and Compliance with UCPMP 2024**


With reference to the subject, we wish to clarify that our organization is currently engaged exclusively in the manufacturing of APIs/Bulk Drugs/Excipients and does not produce any formulation products. Furthermore, we have no intention to manufacture formulation products during the financial year 2024–25.

Should we decide in the future to manufacture formulation products and initiate marketing activities for the domestic market, we hereby commit to adhering to the Uniform Code of Pharmaceutical Marketing Practices (UCPMP) as applicable at that time.

Additionally, we undertake that **Proventus Life Sciences Pvt. Ltd.**, headquartered at **C-9, Industrial Area II (CMDA), Maraimalai Nagar – 603 209, Chengalpattu District, Tamil Nadu - India**, will comply with the provisions of UCPMP 2024 and provide full cooperation and assistance to the authorities in enforcing the code.

Thanking you.

Yours faithfully,



**Ayush Sultania**  
Director,  
Proventus Life Sciences Pvt. Ltd.,

